Human Genome adopts rights plan to ward off Glaxo

(Reuters) – Human Genome Sciences Inc said on Thursday it had adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion hostile takeover bid by drugmaker GlaxoSmithKline Plc. Human Genome said its board determined the $13-a-share bid by the British drugmaker was inadequate and undervalued the company, and it recommended stockholders not tender their shares. …

J&J drug shows promise in high-risk prostate cancer

A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster(Reuters) – Adding Johnson & Johnson’s advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. The mid-stage trial found that six months of treatment with the combination therapy completely or nearly eliminated the cancer in a third of patients, all of whom had localized, aggressive cancer. …

Glaxo melanoma drug combo shows promise in small trial

(Reuters) – Two drugs being developed by GlaxoSmithKline Plc – each designed to block different pathways used by cancer cells – have been shown in a small clinical trial to curb melanoma with fewer side effects than current therapies. The experimental drugs are dabrafenib, designed to work in patients with a mutation of a gene known as BRAF, and trametinib, which interferes with a protein known as MEK. The drug combination was tested in patients with advanced melanoma and a mutation in the BRAF gene. About half of all melanomas – the deadliest form of skin cancer – have the genetic aberration. …

1 57 58 59 60 61 126